Ashton-Rickardt Philip 4
4 · Sigilon Therapeutics, Inc. · Filed Mar 1, 2023
Insider Transaction Report
Form 4
Ashton-Rickardt Philip
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-02-28+115,000→ 115,000 totalExercise: $1.09Exp: 2033-02-27→ Common Stock (115,000 underlying)
Footnotes (1)
- [F1]The option vests as to 25% of the underlying shares of common stock on February 28, 2024, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.